Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04581824
Title	Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	GlaxoSmithKline
Indications	lung non-squamous non-small cell carcinoma
Therapies	Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium
Age Groups:	adult \| senior
Covered Countries	USA \| ITA \| FRA \| ESP \| DEU